drugset
Drugs / L9LS
last change Jun 2026 re-read 2 minutes ago

L9LS

also known as VRC-MALMAB0114-00-AB

Monoclonal antibody

Developed for
malaria · Plasmodium falciparum malaria
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health (NIH) · Indiana University · University of Washington · Harvard School of Public Health (HSPH) · Malaria Research and Training Center, Bamako, Mali
+6 more · University of the Sciences, Techniques and Technologies of Bamako · Centers for Disease Control and Prevention · Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS) · Liverpool School of Tropical Medicine · Kenya Medical Research Institute · University of Sciences, Techniques, and Technologies of Bamako (USTTB)

Trials 8 · a red edge is where a trial was stopped

today NCT07208760 · Ph 2 NCT07060508 · Ph 2 NCT07082205 · Ph 3 NCT06461026 · Ph 1 NCT05816330 · Ph 2 NCT05400655 · Ph 2 NCT05304611 · Ph 2 NCT05019729 · Ph 1
2022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06461026 Aug 2024 → Jun 2025 overdue malaria National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded
Phase 1 NCT05019729 Sep 2021 → Sep 2022 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 25 trials
Phase 2 NCT07208760 Mar 2026 → Mar 2028 malaria National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 2 NCT07060508 Jul 2025 → Apr 2026 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT05816330 May 2023 → Feb 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT05400655 Sep 2022 → Jun 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT05304611 Mar 2022 → Apr 2024 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT07082205 May 2025 → Sep 2026 expected anemia, malaria Liverpool School of Tropical Medicine Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as L9LS “L9LS Antimalarial monoclonal antibodies (mMAbs)” NCT07082205 ↗
6

NCT07060508 ↗

NCT07208760 ↗

NCT06461026 ↗

NCT05816330 ↗

NCT05304611 ↗

NCT05400655 ↗
Known as VRC-MALMAB0114-00-AB “L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection” NCT05304611 ↗
2

“L9LS (VRC-MALMAB0114-00-AB)” NCT05816330 ↗

NCT05019729 ↗
Action Inhibit “to neutralize it and prevent malaria infection” NCT07082205 ↗
Modality Monoclonal antibody “VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.” NCT05019729 ↗
Route Subcutaneous “Administered one time via subcutaneous route.” NCT05304611 ↗